NCT06837129View on ClinicalTrials.gov

Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.

NACompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

August 30, 2025

Conditions

Intrathecal MorphineCaesarean SectionPostoperative Nausea and VomitingNeuraxial Opioid

Interventions

DRUG

A single dose of 4 mg iv nalbuphine

prevention of nausea vomiting

Trial Locations (2)

12121

Department of Anesthesiology, Faculty of Medicine, Thammasat University, Pathum Thani

Faculty of Medicine Thammasat University, Pathum Thani

All Listed Sponsors

lead

Thammasat University

OTHER

NCT06837129 - Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial. | Biotech Hunter | Biotech Hunter